Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742853 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
A Phase 1 study of Dyslipidemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 3
- Study locations
NCT06742853: Completed Phase 1 study of Dyslipidemia, sponsored by AstraZeneca.
NCT06742853 is a Phase 1 study of Dyslipidemia that has completed, run by AstraZeneca. The registered enrollment target is 81 participants, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742853, a Phase 1 study of Dyslipidemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
Primary Outcome
To evaluate the effect of AZD0780 on LDL-C levels versus placebo when dosed with ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
- DRUG Rosuvastatin
- DRUG Bempedoic Acid
- DRUG Ezetimibe
Study Locations (3)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Other
- Research Site - Harrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-10-29 |
| Phase | Phase 1 |
What the finished NCT06742853 record still lists
NCT06742853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06742853 reports a single indexed study location in California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT06742853 about?
NCT06742853 is a clinical study titled "A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.". The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
What is the current status of trial NCT06742853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2024-12-20. Estimated completion is 2025-10-29.
What conditions does trial NCT06742853 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT06742853?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG), Rosuvastatin (DRUG), Bempedoic Acid (DRUG), Ezetimibe (DRUG).
Who is sponsoring clinical trial NCT06742853?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742853 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06742853's enrollment target sits among peer trials
81 24th of 40 higher than 16 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
COMPLETED · Phase 1
-
Effects of Niacin On Fatty Acid Trapping
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI